Structure-activity relationships of different β-lactam antibiotics against a soluble form of Enterococcus faecium PBP5, a type II bacterial transpeptidase

被引:25
|
作者
Hujer, AM
Kania, M
Gerken, T
Anderson, VE
Buynak, JD
Ge, XX
Caspers, P
Page, MGP
Rice, LB
Bonomo, RA
机构
[1] Case Western Reserve Univ, Louis Stokes Cleveland Vet Affairs Med Ctr, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA
[3] Basilea Pharmaceut Ltd, Basel, Switzerland
[4] So Methodist Univ, Dept Chem, Dallas, TX 75275 USA
关键词
D O I
10.1128/AAC.49.2.612-618.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Penicillin-binding proteins (PBPs) catalyze the essential reactions in the biosynthesis of cell wall peptidoglycan from glycopeptide precursors. P-Lactam antibiotics normally interfere with this process by reacting covalently with the active site serine to form a stable acyl-enzyme. The design of novel beta-lactams active against penicillin-susceptible and penicillin-resistant organisms will require a better understanding of the molecular details of this reaction. To that end, we compared the affinities of different P-lactam antibiotics to a modified soluble form of a resistant Enterococcus faecium PBP5 (Delta1-36 rPBP5). The soluble protein, Delta1-36 rPBP5, was expressed in Escherichia coli and purified, and the NH2-terminal protein sequence was verified by amino acid sequencing. Using beta-lactams with different R1 side chains, we show that azlocillin has greater affinity for Delta1-36 rPBP5 than piperacillin and ampicillin (apparent K-i = 7 +/- 0.3 muM, compared to 36 +/- 3 and 51 +/- 10 muM, respectively). Azlocillin also exhibits the most rapid acylation rate (apparent k(2) = 15 +/- 4M(-1) s(-1)). Meropenem demonstrates an affinity for Delta1-36 rPBP5 comparable to that of ampicillin (apparent K-2 = 51 Delta 15 muM) but is slower at acylating (apparent k(2) = 0.14 +/- 0.02 M-1 s(-1)). This characterization defines important structure-activity relationships for this clinically relevant type II transpeptidase, shows that the rate of formation of the acyl-enzyme is an essential factor determining the efficacy of a P-lactam, and suggests that the specific side chain interactions of beta-lactams could be modified to improve inactivation of resistant PBPs.
引用
收藏
页码:612 / 618
页数:7
相关论文
共 3 条
  • [1] Activity of Ceftaroline against Enterococcus faecium PBP5
    Henry, Xavier
    Verlaine, Oliver
    Amoroso, Ana
    Coyette, Jacques
    Frere, Jean-Marie
    Joris, Bernard
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (12) : 6358 - 6360
  • [2] Discovery and structure-activity relationships of a novel isothiazolone class of bacterial type II topoisomerase inhibitors
    Cooper, Ian R.
    McCarroll, Andrew J.
    McGarry, David
    Kirkham, James
    Pichowicz, Mark
    Walker, Rolf
    Warrilow, Catherine
    Salisbury, Anne-Marie
    Savage, Victoria J.
    Moyo, Emmanuel
    Forward, Henry
    Cheung, Jonathan
    Metzger, Richard
    Gault, Zoe
    Nelson, Gary
    Hughes, Diarmaid
    Cao, Sha
    Maclean, John
    Charrier, Cedric
    Craighead, Mark
    Best, Stuart
    Stokes, Neil R.
    Ratcliffe, Andrew J.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (17) : 4179 - 4183
  • [3] Discovery and structure-activity relationships of a novel oxazolidinone class of bacterial type II topoisomerase inhibitors
    Lyons, Amanda
    Kirkham, James
    Blades, Kevin
    Orr, David
    Dauncey, Elizabeth
    Smith, Oliver
    Dick, Emma
    Walker, Rolf
    Matthews, Teresa
    Bunt, Adam
    Finlayson, Jonathan
    Morrison, Ian
    Savage, Victoria J.
    Moyo, Emmanuel
    Butler, Hayley S.
    Newman, Rebecca
    Ooi, Nicola
    Smith, Andrew
    Charrier, Cedric
    Ratcliffe, Andrew J.
    Stokes, Neil R.
    Best, Stuart
    Salisbury, Anne-Marie
    Craighead, Mark
    Cooper, Ian R.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2022, 65